Cytokeratin 19 (CK19) as a marker for Epithelial Differentiation and Malignant Transformation

Its Clinical relevance in Diagnosis, Prognosis and Treatment response monitoring

BONAVENTURE MUJYAMBERE, Rama Jayaraj, Suja S

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Cytokeratin 19 (CK19) is a type I cytokeratin found mostly in epithelial tissues with high plasticity such as stem cells, transforming cells or tumorous cells. CK19 increases its expression level during epithelial embryogenesis, tissues regeneration, tissue repair as well as tissue development and has shown to have an increasing expression in carcinogenesis of CK19-positive cancers from normal tissues to premalignant lesions to carcinoma in situ. The insertion of CK19 in CK19-negative carcinoma cells induced the metastatic progression characterized by angiogenesis, invasion to surrounding tissues, increased proliferation and drug resistance. Hence, the detection of intracellular CK19 protein by immunohistochemistry (IHC), CK19 transcripts by quantitative Real time RT-PCR or One-step nucleic acid amplification (OSNA) and serum CK19 fragments such as Cyfra 21-1 by enzyme-linked immunosorbent assay (ELISA) could help in diagnosis to confirm the presence of the cancerous cells, in prognosis to predict the course the cancer is mostly likely to take and in treatment response monitoring to investigate the effectiveness of the treatment so that the early adjuvant therapy could be used in case the treatment was found ineffective during the follow-up studies.
Original languageEnglish
Article number1700752
Pages (from-to)51-61
Number of pages11
JournalIRE Journals
Volume2
Issue number3
Publication statusPublished - Sep 2018

Fingerprint

Keratin-19
Differentiation Antigens
Therapeutics
Epithelium
Carcinoma in Situ
Keratins
Secondary Prevention
Drug Resistance
Nucleic Acids
Embryonic Development
Real-Time Polymerase Chain Reaction
Regeneration
Neoplasms
Carcinogenesis
Stem Cells
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Carcinoma

Cite this

@article{2b0514813f7e4077b1f51ba4b755a494,
title = "Cytokeratin 19 (CK19) as a marker for Epithelial Differentiation and Malignant Transformation: Its Clinical relevance in Diagnosis, Prognosis and Treatment response monitoring",
abstract = "Cytokeratin 19 (CK19) is a type I cytokeratin found mostly in epithelial tissues with high plasticity such as stem cells, transforming cells or tumorous cells. CK19 increases its expression level during epithelial embryogenesis, tissues regeneration, tissue repair as well as tissue development and has shown to have an increasing expression in carcinogenesis of CK19-positive cancers from normal tissues to premalignant lesions to carcinoma in situ. The insertion of CK19 in CK19-negative carcinoma cells induced the metastatic progression characterized by angiogenesis, invasion to surrounding tissues, increased proliferation and drug resistance. Hence, the detection of intracellular CK19 protein by immunohistochemistry (IHC), CK19 transcripts by quantitative Real time RT-PCR or One-step nucleic acid amplification (OSNA) and serum CK19 fragments such as Cyfra 21-1 by enzyme-linked immunosorbent assay (ELISA) could help in diagnosis to confirm the presence of the cancerous cells, in prognosis to predict the course the cancer is mostly likely to take and in treatment response monitoring to investigate the effectiveness of the treatment so that the early adjuvant therapy could be used in case the treatment was found ineffective during the follow-up studies.",
author = "BONAVENTURE MUJYAMBERE and Rama Jayaraj and Suja S",
year = "2018",
month = "9",
language = "English",
volume = "2",
pages = "51--61",
journal = "IRE Journals",
issn = "2456-8880",
number = "3",

}

Cytokeratin 19 (CK19) as a marker for Epithelial Differentiation and Malignant Transformation : Its Clinical relevance in Diagnosis, Prognosis and Treatment response monitoring. / MUJYAMBERE, BONAVENTURE; Jayaraj, Rama; S, Suja.

In: IRE Journals, Vol. 2, No. 3, 1700752, 09.2018, p. 51-61.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cytokeratin 19 (CK19) as a marker for Epithelial Differentiation and Malignant Transformation

T2 - Its Clinical relevance in Diagnosis, Prognosis and Treatment response monitoring

AU - MUJYAMBERE, BONAVENTURE

AU - Jayaraj, Rama

AU - S, Suja

PY - 2018/9

Y1 - 2018/9

N2 - Cytokeratin 19 (CK19) is a type I cytokeratin found mostly in epithelial tissues with high plasticity such as stem cells, transforming cells or tumorous cells. CK19 increases its expression level during epithelial embryogenesis, tissues regeneration, tissue repair as well as tissue development and has shown to have an increasing expression in carcinogenesis of CK19-positive cancers from normal tissues to premalignant lesions to carcinoma in situ. The insertion of CK19 in CK19-negative carcinoma cells induced the metastatic progression characterized by angiogenesis, invasion to surrounding tissues, increased proliferation and drug resistance. Hence, the detection of intracellular CK19 protein by immunohistochemistry (IHC), CK19 transcripts by quantitative Real time RT-PCR or One-step nucleic acid amplification (OSNA) and serum CK19 fragments such as Cyfra 21-1 by enzyme-linked immunosorbent assay (ELISA) could help in diagnosis to confirm the presence of the cancerous cells, in prognosis to predict the course the cancer is mostly likely to take and in treatment response monitoring to investigate the effectiveness of the treatment so that the early adjuvant therapy could be used in case the treatment was found ineffective during the follow-up studies.

AB - Cytokeratin 19 (CK19) is a type I cytokeratin found mostly in epithelial tissues with high plasticity such as stem cells, transforming cells or tumorous cells. CK19 increases its expression level during epithelial embryogenesis, tissues regeneration, tissue repair as well as tissue development and has shown to have an increasing expression in carcinogenesis of CK19-positive cancers from normal tissues to premalignant lesions to carcinoma in situ. The insertion of CK19 in CK19-negative carcinoma cells induced the metastatic progression characterized by angiogenesis, invasion to surrounding tissues, increased proliferation and drug resistance. Hence, the detection of intracellular CK19 protein by immunohistochemistry (IHC), CK19 transcripts by quantitative Real time RT-PCR or One-step nucleic acid amplification (OSNA) and serum CK19 fragments such as Cyfra 21-1 by enzyme-linked immunosorbent assay (ELISA) could help in diagnosis to confirm the presence of the cancerous cells, in prognosis to predict the course the cancer is mostly likely to take and in treatment response monitoring to investigate the effectiveness of the treatment so that the early adjuvant therapy could be used in case the treatment was found ineffective during the follow-up studies.

M3 - Article

VL - 2

SP - 51

EP - 61

JO - IRE Journals

JF - IRE Journals

SN - 2456-8880

IS - 3

M1 - 1700752

ER -